How Long Does Remicade Stay in Your Body?
Remicade (infliximab), a biologic drug for autoimmune conditions like Crohn's disease and rheumatoid arthritis, has a half-life of 8 to 9.5 days in most patients.[1] This means half the drug is cleared after that time, with full elimination typically taking 4-6 half-lives, or about 5-8 weeks.[1][2] Steady-state levels build up over multiple infusions, so it lingers longer with regular dosing every 6-8 weeks.
What Affects Clearance Time?
Factors like body weight, age, and disease activity influence how long Remicade remains detectable. Higher body weight shortens half-life (e.g., 8 days at 30 kg vs. 11.5 days at 100 kg); patients with elevated baseline CRP (inflammation marker) clear it faster.[1] Antibodies to infliximab, which develop in up to 30% of patients without immunosuppressants, accelerate clearance and reduce effectiveness.[2][3]
How Is Remicade Detected After Treatment?
Blood tests measure serum levels. Therapeutic concentrations (3-7 mcg/mL) persist 4-12 weeks post-infusion, depending on dose (3-10 mg/kg).[2] It becomes undetectable by ELISA or other assays after 8-12 weeks in most cases, though trace amounts may remain longer in tissues.[3]
What Happens If You Stop Remicade Suddenly?
Drug levels drop gradually, with disease flares possible 8-12 weeks later as levels fall below therapeutic range.[2] No acute withdrawal syndrome occurs, but immunogenicity rises upon restarting, potentially worsening response.[3]
How Does This Compare to Similar Drugs?
| Drug | Half-Life | Dosing Interval | Clearance Time |
|------|-----------|-----------------|---------------|
| Remicade (infliximab) | 8-9.5 days | Every 6-8 weeks | 5-8 weeks |
| Humira (adalimumab) | 10-20 days | Every 1-2 weeks | 2-4 months |
| Stelara (ustekinumab) | 21 days | Every 8-12 weeks | 3-5 months |
| Simponi (golimumab) | 11-18 days | Monthly | 2-3 months |
Remicade clears faster than subcutaneous TNF inhibitors due to its chimeric structure and IV administration.[2][4]
Patient Concerns: Detection in Drug Tests or Pregnancy?
Remicade does not trigger standard urine drug screens (e.g., for opioids). In pregnancy, it crosses the placenta minimally after 30 weeks; neonatal levels decline over 3-6 months post-birth.[3] Breastfeeding passes negligible amounts.[1]
[1]: Remicade Prescribing Information (Janssen)
[2]: Pharmacokinetics of Infliximab (Drugs.com)
[3]: Infliximab in Pregnancy (MotherToBaby)
[4]: TNF Inhibitor Comparison (Arthritis.org)